| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Check-Cap Ltd.
$8.04
0 (0%)
Market Cap
76.08 M
EPS
0.74
P/E Ratio
10.89 $
Value Trade
119.91 K
-3.83 %
Week
651.4 %
1 Month
367.44 %
3 Month
415.38 %
6 Month
-99.7 %
5 Year
-100 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
15.19 K
52 Week Range
0.59 - 3.92
% held by Insiders
20.82 %
% held by Institutions
0.84 %
Enterprise Value
12.29 M
Total Shares
9.46 M
Short %
1.28 %
Float Shares
4.56 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Check-Cap Ltd.
14Total events
1Upcoming
7Tier-1 (high impact)
2024 – 2026Coverage
Upcoming catalysts 1
TBD
T1Partnership / License
Subscribe to view catalyst details
Event history 2
TBD
▲Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲FDA Filing AcceptedRegulatory Filing
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
MBAI Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MBAI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MBAI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MBAI▲ +6.3%on this news· ran to +26% by day 1
MBody AI Corp, Inc. Index to Financial Statements Table of Contents Page Report of Independent Registered Public Accounting Firm (PCAOB Firm ID: 7158) 2 Financial Statements Balance Sheets 4 Statements of Operations 5 St
MBody AI Corp has released its financial statements audited for the year ending December 31, 2025. The audit indicates that the financial position and results of operations are presented fairly, adhering to GAAP principles. Notably, the company reported significant revenues from customer subscription contracts, leading to a positive net income for the period. The total assets have substantially increased, reflecting growth in the company’s financial standing.
Read more →MBAIMBody AI Corp. Expands Fortune 500 Deployment, Advancing National Robotics Rollout Proven pilot converts to multi-property expansion; deployment remains less than 10% of national footprint ISFIYA, ISRAEL & NEVADA
MBody AI Corp. has announced the expansion of its deployment with a Fortune 500 gaming and hospitality operator, transitioning from a pilot program to a multi-property rollout. This expansion leverages successful live operations that demonstrated consistent performance. Currently, the deployment covers less than 10% of the operator's national footprint, indicating significant growth potential in the relationship. The agreement involves autonomous floor care with plans to broaden services across various categories, contributing to a recurring revenue model.
Read more →MBAIMBody AI and Check Cap Ltd. ($MBAI) Submit Nasdaq Listing Application for Merger Close Proposed Nasdaq-listed AI company achieves key regulatory milestone as merger with Check-Cap targets first half of 2026; $30M growth
MBody AI has submitted its Nasdaq listing application, marking a key regulatory step towards the merger with Check-Cap Ltd. This move is anticipated to facilitate the combined company's successful listing on Nasdaq by the first half of 2026. Recent milestones include regaining compliance with Nasdaq requirements and filing important financial documentation. Both company leaders express optimism about the future, emphasizing the potential for significant opportunities in the embodied AI market.
Read more →MBAI▼ -11.1%on this news· ran to -23% by day 1
MBody AI Corp, Inc. Index to Financial Statements Table of Contents Page Report of Independent Registered Public Accounting Firm (PCAOB Firm ID: 7158) 2 Financial Statements Balance Sheets 3 Statements of Operations 4 St
MBody AI Corp has released its financial statements for the period ending June 30, 2025. The audit report indicates the statements present an accurate depiction of the company’s finances, despite a net loss reported during this period. The transition toward a software-as-a-service model could enhance future revenue streams, while current operating expenses have risen significantly, raising concerns about financial sustainability.
Read more →MBAI▲ +112.1%on this news
Check-Cap Clears Key Nasdaq Requirement, Advancing MBody AI Merger Toward Completion Milestone achieved as shareholder-approved merger with MBody AI remains on track ISFIYA, ISRAEL
Check-Cap Ltd. has confirmed its compliance with Nasdaq's minimum shareholders' equity requirements, a crucial step towards finalizing the merger with MBody AI. This merger, which has already garnered 98% shareholder approval, aims to position Check-Cap as a leader in the embodied artificial intelligence sector. The transition to being a publicly traded entity is anticipated to enhance the visibility and scalability of MBody AI's technology across various industries. With this regulatory clearance, Check-Cap is now focused on the execution of final transaction steps.
Read more →MBAIConsolidated Unaudited Financial Statements of Check-Cap Ltd. A s of and for the six months ended
Check-Cap Ltd. released its unaudited financial statements for the six months ending June 30, 2025. The company reported significant improvements in total current assets and a turnaround in net income, reaching $5.213 million. However, persistent accumulated deficits and the discontinuation of research and development activities raise concerns about the company's ongoing viability, as it evaluates strategic alternatives and a planned merger with MBody AI Corp. The management's assessment of going concern remains uncertain owing to limited revenue generation and high liabilities.
Read more →MBAI▼ -11.8%on this news
MBody AI To Begin Trading Under New Nasdaq Ticker Symbol "MBAI" $MBAI Ticker change for Check-Cap's ($MBAI) transformation into a publicly traded embodied-AI company and ongoing strategy to scale enterprise automation wi
MBody AI Corp. announced its transition to a new Nasdaq ticker symbol "MBAI", effective December 2, 2025, following its merger with Check-Cap Ltd. This change marks the company's evolution into a publicly traded leader in embodied artificial intelligence. The firm seeks to drive enterprise automation through a hardware-agnostic AI platform capable of integrating diverse robotic and sensor systems. Both leadership executives expressed confidence in the company's position within the rapidly evolving AI landscape.
Read more →MBAIMBody AI ($CHEK) Secures 98% Shareholder Approval to Become Leading Nasdaq Embodied AI Company Nasdaq-listed AI company gains overwhelming shareholder support for its transformational merger, positioning MBody AI ($CHEK)
MBody AI Corp. has received overwhelming support from Check-Cap shareholders, with over 98% voting in favor of their merger, which is expected to close shortly. This merger will establish MBody AI as a key player in the embodied AI sector on Nasdaq. The company provides a hardware-agnostic platform aimed at automating operations across multiple industries, appealing particularly to enterprises seeking efficiency and scalability in their processes.
Read more →MBAICheck-Cap Ltd. Check-Cap Building 29 Abba Hushi Avenue P.O. Box 1271 Isfiya, 3009000 Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the Annual General Meeting
Check-Cap Ltd. has announced its upcoming Annual General Meeting scheduled for October 17, 2025. At this meeting, shareholders will vote on a proposal for the merger with MBody AI, which will also result in a name change for Check-Cap. Additionally, management representatives will review the company's financial statements for the fiscal year ending December 31, 2024. The merger is anticipated to create synergies and expand operational capabilities in various sectors.
Read more →MBAICHECK CAP LTD CONSOLIDATED UNAUDITED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) June 30
Check Cap Ltd reported its unaudited consolidated balance sheets, revealing a drop in total assets to $18,090 thousand as of June 30, 2024, down from $25,017 thousand at year-end 2023. The company posted a net loss of $6,312 thousand for the first half of 2024, showcasing a steep increase in its accumulated deficit. Notably, the firm has halted its ongoing calibration studies and decided against initiating the powered portion of its pivotal study due to prior efficacy results not meeting expectations. This decision accompanies significant workforce reductions aimed at preserving cash flow amidst ongoing operational challenges.
Read more →MBAICheck-Cap Ltd. Check-Cap Building 29 Abba Hushi Avenue P.O. Box 1271 Isfiya, 3009000 Israel AMENDED NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: On
Check-Cap Ltd. has announced an amended notice for an Extraordinary General Meeting of Shareholders scheduled for April 25, 2024, at The Ritz Carlton in Toronto, Canada. The amendment reflects a change in the meeting's location, but no alterations have been made to the proposed resolutions. Shareholders of record will be entitled to vote on various proposals, including compensation and board member appointments. The company ensures that shareholders have clear instructions on how to participate and vote during the meeting.
Read more →MBAIPROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS This Proxy Statement is furnished to our holders of ordinary shares, par value NIS 48.00 (the "Ordinary Shares"), in connection with Extraordinary General Mee
Check-Cap Ltd. is holding an Extraordinary General Meeting for shareholders on April 25, 2024. Shareholders with Ordinary Shares as of March 25, 2024, are eligible to vote on various proposals. The Board of Directors recommends that shareholders vote in favor of proposals 1 to 7. Additionally, guidelines for proxy voting and meeting procedures are outlined in the statement. A quorum of at least 25% of voting rights is required for the meeting to proceed.
Read more →MBAIBUSINESS COMBINATION AGREEMENT BETWEEN NOBUL AI CORP. - AND - CHECK-CAP LTD. DATED AS OF MARCH 25, 2024 TABLE OF CONTENTS Article 1 DEFINITIONS AND INTERPRETATION 1 1.1 Certain Definitions. 1 1.2 Further Definitions. 14
Nobul AI Corp. and Check-Cap Ltd. have entered into a business combination agreement as of March 25, 2024. The agreement outlines the merger process where a wholly owned subsidiary of Nobul will merge with Check-Cap. The Check-Cap Board has reviewed the merger and deemed it fair and advisable for its shareholders, backed by an independent financial advisor's approval. This agreement highlights the intention of both parties to enhance their business operations and shareholder value through this strategic merger.
Read more →MBAIGraham Schmidt
Graham Schmidt has announced his resignation from the Board of Directors of Check-Cap Ltd, effective January 22, 2024. He expressed gratitude for the opportunity to serve and extended his best wishes for the company's future. This decision comes after careful consideration, and Schmidt looks forward to observing Check-Cap's continued progress.
Read more →Competitive Position
How MBAI ranks across every disease it competes inCompetitive Position is a premium feature
See how MBAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial